You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Genmab A/S disclosed that directors Martin Schultz and Mijke Zachariasse sold 617 shares and 351 shares, respectively, at DKK 3,540.87 on November 12, 2026.
Genmab A/S disclosed that Bradley Bailey sold 1,071 shares on 2026-11-11 at an aggregated price of DKK 3,602.98 on NASDAQ Copenhagen (XCSE).
Genmab A/S set share capital at DKK 62,570,683 and authorized its board through March 12, 2029 to increase capital by up to nominally DKK 6,600,000.
GenMab reported three positive phase three trials, including a 0.49 hazard ratio for frontline DLBCL and overall survival benefits for RENA and Pitocentumab, while retaining prior peak sales guidance.
Genmab A/S will increase its share capital by 164,828 shares following employee warrant exercises, raising approximately DKK 369.7 million. The increase represents approximately 0.2641% of share capital and is expected to be finalized shortly.
GenMap reported 22% revenue growth for the first nine months of 2026, three Phase III readouts, and expects revenue in the upper part of its $4.325 billion to $4.525 billion range.
Genmab reported first-nine-month 2026 revenue of $3,238 million, up 22%, while Phase 3 trials for epcoritamab, Rina-S and petosemtamab delivered positive topline results.
Genmab’s Phase 3 LiGeR-HN1 trial found petosemtamab plus pembrolizumab reduced death risk by 50% and met both primary endpoints in first-line PD-L1 positive recurrent/metastatic HNSCC, regardless of HPV status; global regulatory engagement is planned.
Genmab A/S said the Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®) met progression-free survival and overall survival endpoints in platinum-resistant ovarian cancer. Rina-S reduced progression or death risk by 71% in the ITT population and 67% in PAS.
Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) of USD 4,239 million in the third quarter of 2026 and receives royalties on worldwide net sales from Johnson & Johnson.
Genmab A/S’s Board remuneration proposal for 2026 was approved at an Extraordinary General Meeting, resulting in 5,300 restricted stock units granted to Board members. Each unit has a fair value of DKK 2,487.00.
Genmab and AbbVie said Phase 3 EPCORE DLBCL-2 showed epcoritamab plus R-CHOP significantly improved progression-free survival in newly diagnosed DLBCL, reducing progression or death risk by 51% (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001).
Genmab A/S announced that Darwin Global Management Limited controlled voting rights attached to 3,188,361 shares, corresponding to 5.11% of Genmab A/S’s voting rights, as of September 28, 2026.
Genmab A/S’s Articles of Association dated September 24, 2026 set share capital at DKK 62,405,855 divided into DKK 1 shares and authorize the board, through March 12, 2029, to increase capital by up to nominally DKK 6,600,000.
On September 24, 2026, Genmab A/S's Board granted employees 13,794 restricted stock units and 13,331 warrants. The units vest after three years, while warrants have a DKK 2,268 exercise price and expire at the seventh grant anniversary.
GenMap guides q4 readouts for epkidney in dlbcl, rena s in second line platinum-resistant ovarian cancer, and pitocentamab in frontline head and neck cancer, and anticipates launching all three assets in 2027.
